Beam Therapeutics Files 2023 Annual Report on Form 10-K

TL;DR

<b>Beam Therapeutics Inc. has submitted its comprehensive 2023 annual report (10-K) detailing its financial performance and operational status.</b>

AI Summary

Beam Therapeutics Inc. (BEAM) filed a Annual Report (10-K) with the SEC on February 27, 2024. Beam Therapeutics Inc. filed its 2023 Form 10-K on February 27, 2024. The company is incorporated in Delaware and operates in the Biological Products sector. Its principal business address is 26 Landsdowne Street, Cambridge, MA 02139. The filing covers the fiscal year ending December 31, 2023. The SEC file number for this report is 001-39208.

Why It Matters

For investors and stakeholders tracking Beam Therapeutics Inc., this filing contains several important signals. This 10-K filing provides investors and stakeholders with a detailed overview of Beam Therapeutics' financial health, strategic initiatives, and risk factors for the fiscal year 2023. The report is crucial for understanding the company's progress in the competitive biotechnology landscape, particularly in gene editing technologies.

Risk Assessment

Risk Level: medium — Beam Therapeutics Inc. shows moderate risk based on this filing. The company operates in the highly regulated and competitive biotechnology sector, facing risks related to clinical trial success, regulatory approvals, and intellectual property.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to assess Beam Therapeutics' long-term viability and growth potential in the gene editing market.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-02-27 — Filing Date (Filed as of date)
• 113 — Public Document Count (Number of documents in the filing)
• 0000950170-24-020622 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Beam Therapeutics Inc. (company) — Filer name
• 26 LANDSDOWNE STREET (address) — Business address
• CAMBRIDGE (location) — Business address city
• MA (location) — Business address state
• 02139 (postal_code) — Business address zip
• 001-39208 (filing_id) — SEC file number
• DE (location) — State of incorporation
• 2836 (sic_code) — Standard Industrial Classification

FAQ

Industry Context

Beam Therapeutics operates in the biotechnology industry, focusing on the development of next-generation gene editing technologies.

Regulatory Implications

As a biotechnology company, Beam Therapeutics is subject to stringent regulatory oversight from bodies like the FDA regarding drug development and clinical trials.

What Investors Should Do

1. Analyze Beam Therapeutics' financial health and operational progress detailed in the 10-K.
2. Evaluate the company's competitive positioning and future growth prospects in the gene editing market.
3. Assess the identified risks and their potential impact on the company's performance.

Key Dates

• 2024-02-27: 10-K Filing — Annual report submission date
• 2023-12-31: Fiscal Year End — End date of the reporting period

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year ending December 31, 2023, providing a baseline for future comparisons.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select

Filing Documents

• beam-20231231.htm (10-K) — 3919KB
• beam-ex10_29.htm (EX-10.29) — 18KB
• beam-ex10_39.htm (EX-10.39) — 32KB
• beam-ex10_40.htm (EX-10.40) — 39KB
• beam-ex10_41.htm (EX-10.41) — 34KB
• beam-ex23_1.htm (EX-23.1) — 4KB
• beam-ex31_1.htm (EX-31.1) — 28KB
• beam-ex31_2.htm (EX-31.2) — 28KB
• beam-ex32_1.htm (EX-32.1) — 8KB
• beam-ex32_2.htm (EX-32.2) — 9KB
• beam-ex97_1.htm (EX-97.1) — 30KB
• img43059740_0.jpg (GRAPHIC) — 460KB
• img43059740_1.jpg (GRAPHIC) — 345KB
• img55914526_0.jpg (GRAPHIC) — 1KB
• 0000950170-24-020622.txt (&nbsp;) — 17066KB
• beam-20231231.xsd (EX-101.SCH) — 2242KB
• beam-20231231_htm.xml (XML) — 2674KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 46 Item 1B. Unresolved Staff Comments 110 Item 1C. Cybersecurity 110 Item 2.

Properties

Properties 111 Item 3.

Legal Proceedings

Legal Proceedings 111 Item 4. Mine Safety Disclosures 111 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 112 Item 6. [Reserved] 114 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 115 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 126 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 126 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 126 Item 9A.

Controls and Procedures

Controls and Procedures 126 Item 9B. Other Information 129 Item 9C Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 129 PART III Item 10. Directors, Executive Officers and Corporate Governance 130 Item 11.

Executive Compensation

Executive Compensation 130 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 130 Item 13. Certain Relationships and Related Transactions, and Director Independence 130 Item 14. Principal Accounting Fees and Services 130 PART IV Item 15. Exhibits, Financial Statement Schedules 131 Item 16. Form 10-K Summary 134 CAUTIONARY NOTE REGARDING FORWARD-LOOK ING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward-looking statements reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "anticipate," "expect," "suggest," "plan," "believe," "intend," "project," "forecast," "estimates," "targets," "projections," "should," "could," "would," "may," "might," "will," and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of important risks, uncertainties and assumptions, including those described in "Risk Factors Summary" and in "Risk Factors" in Part I, Item 1A of this report. Unless legally required, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. These forward-looking statements re

B usiness

Item 1. B usiness. Overview We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. This approach uses a chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, with the potential to dramatically increase the impact of gene editing. We are also pursuing a suite of delivery modalities, including both ex vivo and in vivo approaches, depending on tissue type. The elegance of the base editing approach, combined with a tissue specific delivery modality, provides the basis for a targeted, efficient, precise, and highly versatile gene editing system that is designed to be capable of gene correction, gene silencing, gene activation, gene modification, and/or multiplex editing of several genes simultaneously. Our goal is to advance a broad, diversified portfolio of base editing programs against distinct, gene